Medimmune Limited

Binyam Bezabeh

Changshou Gao

Nazzareno Dimasi

Ryan Fleming

Ralph Raymond Minter

Partha S Chowdhury

Melissa Marie Damschroder

Charles K Stover

Bret Sellman

Godfrey Rainey

Reena Varkey

Sandrine Guillard

Cuihua Gao

Steven Rust

Antonio Digiandomenico

Paul Warrener

Mladen Tomich

Vignesh Venkatraman

Li Peng

John H Li

Andy Q Yuan

Srinath Kasturirangan

Steven Roy Coats

Dorin Toader

Lakshmaiah Gingipalli

Fengjiang Wang

Ralph Minter

Andy Qingan Yuan

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.

Multispecific and multivalent binding proteins and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Binyam Bezabeh